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The insulin growth factor pathway (IGF), a complex onewith multiple receptors and ligands, is involved in essen-
tial steps of cancer development such as survival, prolifera-
tion, and metastases.1 Although expression of IGF signaling
seems to have prognostic significance, predictive factors for
benefit have not yet been identified. Cross talk between the
IGF and other pathways, particularly EFGR, may be impor-
tant for understanding and mitigating resistance. Several
compounds, including monoclonal antibodies and tyrosine
kinase inhibitors, are currently under clinical investigation for
inhibition of the IGF pathway.
SUMMARY OF PRESENTATIONS
Monoclonal Antibodies Against IGF1R
Dr. Ross Camidge presented data on IMC-A12, a
monoclonal antibody with high affinity to IGF1R. Early trials
revealed prolonged tumor stabilization in a variety of tumors,
with an acceptable toxicity profile, primarily hyperglycemia
and fatigue,2 which are in fact common to all monoclonal
antibodies that target IGF1R. A phase II randomized trial of
erlotinib with or without A12 in previously treated patients
with NSCLC is ongoing, along with a more recently activated
first-line trial of carboplatin, gemcitabine, and cetuximab,
with or without A12.
Dr. Karen Kelly showed data on another anti-IGF1R
monoclonal antibody, MK-0646. After a phase I trial defined
the optimal dose and schedule and demonstrated favorable
toxicity,3 a randomized phase II trial of cisplatin and
pemetrexed with or without MK-0646 has been launched
(“IMPACT”), along with a trial of erlotinib with or without
MK-0646 in recurrent disease. Dr. Jeremy Barton presented
information on BIIB022, also an anti-IGF1R antibody, which
demonstrated antitumor activity in multiple xenograft mod-
els, and is currently undergoing phase I testing, with plans to
initiate phase II studies in NSCLC in the near future.
Dr. Daniel Karp presented the figitumumab (CP-751, 871)
data, the only anti-IGF1R monoclonal antibody that has reached
phase III testing. A multicenter phase II randomized trial com-
pared carboplatin-paclitaxel alone with the same chemotherapy
plus two doses of fugitumumab as first-line therapy in advanced
NSCLC.4 The study showed higher response rates with the
antibody in both arms but more evident at a dose of 20 mg/kg.
More importantly, patients with squamous cell histology had a
very high-response rate of 78%, confirmed in a dedicated cohort.
Median PFS was also improved with the addition of fugitu-
mumab. Based on these promising data, there is an ongoing
phase III trial in patients with first-line squamous cell cancer.
Dr. Jeffrey Crawford showed data on AMG 479, an
anti-IGF1R monoclonal antibody that yielded promising
results as a single agent and in combination with gemcit-
abine or panitunumab.5 These trials established the optimal
dose of AMG for studies in ovarian, pancreatic, colorectal,
and non-small cell lung cancer, among others, but none
have been completed yet. Dr. Geoge Blumenschein showed
preliminary data on AVE 1642 as a single agent and in
combination with docetaxel. Ongoing trials with this
compound include hormone-dependent breast cancer and
hepatocarcinoma.
IGF Receptor Tyrosine Kinase Inhibitors
Inhibition of the IGF pathway can also be accom-
plished by tyrosine kinase inhibitors, such as BMS-536924,
presented by Dr. Haluska, which is currently limited to
preclinical data, with plans for further testing in NSCLC in
the near future.
SUMMARY
Inhibition of IGF pathway seems to be a promising area
of research in lung cancer. The early-phase II results of
figitumumab are quite promising. Ongoing phase III studies
will define the role of this class of agents in the treatment of
patients with NSCLC in the very near future.
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